A RANDOMIZED CONTROLLED TRIAL OF PANRETINAL PHOTOCOAGULATION WITH AND WITHOUT INTRAVITREAL RANIBIZUMAB IN TREATMENT-NAIVE EYES WITH NON–HIGH-RISK PROLIFERATIVE DIABETIC RETINOPATHY. Issue 2 (February 2015)

• Record Type: Journal Article
• Authors: Ferraz, Daniel A.; Vasquez, Lisa M.; Preti, Rony C.; Motta, Augusto; Sophie, Raafay; Bittencourt, Millena G.; Sepah, Yasir J.; Monteiro, MÁrio L. R.; Nguyen, Quan dong; Takahashi, Walter yukihiko
• Is Part Of: Retina. Volume 35:Issue 2(2015:Feb.)
• Publication Date: 2015-02
• Subjects: proliferative diabetic retinopathy -- ranibizumab -- panretinal photocoagulation; Retina -- Diseases -- Periodicals; Retinal Diseases; Vitreous Body; 617.735
• DOI: 10.1097/IAE.0000000000000363
• Languages: English
• ISSNs: 0275-004X

Abstract

Abstract : Purpose: To compare the efficacy of panretinal photocoagulation (PRP) and intravitreal ranibizumab injection with PRP alone in patients with treatment-naive bilateral non–high-risk proliferative diabetic retinopathy. Methods: Sixty eyes of 30 patients were randomized either to the study group (SG) receiving PRP plus 2 ranibizumab injections or to the control group (CG) receiving PRP alone. Mean change in best-corrected visual acuity and in optical coherence tomography were compared at baseline and 1, 3, and 6 months. Results: Best-corrected visual acuity was significantly better at 6 months in the SG; however, there was decrease in best-corrected visual acuity in the CG. Central macula thickness decreased significantly at 6 months in SG when compared with baseline (−47.6 μ m, P < 0.001) and did not reveal significant difference in the CG. In eyes with diabetic macular edema, best-corrected visual acuity increased by 3.6 letters ( P = 0.06) in the SG and decreased by 4.4 letters in the CG ( P = 0.003). Central macula thickness decreased by 69.3 μ m ( P = 0.001) in the SG and decreased by 45.5 μ m ( P = 0.11) in the CG. Conclusion: Intravitreal ranibizumab in combination with PRP can be an effective treatment in eyes with non–high-risk proliferative diabetic retinopathy and diabetic macular edema. Abstract : Intravitreal ranibizumab in combination with PRP can be an effective treatment in eyes with non–high-risk proliferative diabetic retinopathy and diabetic macular edema.